Navigation Links
Archimedes Pharma Announces Successful Proof-of-Concept Results on Two Intranasal Development Projects
Date:2/26/2009

READING, England, February 26 /PRNewswire/ --

- Intranasal Apomorphine for the Treatment of Motor Fluctuations in Advanced Parkinson's Disease

- Intranasal Diazepam for the Treatment of Acute Repetitive Seizures in Epilepsy

- Phase II Trials on Both Projects to be Initiated During 2009

Archimedes Pharma Limited, the pan-European specialty pharmaceutical company, today announces positive headline data from its recently completed proof-of-concept trials for two of its intranasal (IN) development projects. Both the IN Apomorphine and IN Diazepam Phase I studies showed high bioavailability, positive pharmacokinetics and good tolerability and confirmed that each candidate has the potential to replace existing formulations in high value markets. The agents are being developed for the treatment of motor fluctuations or "off episodes" in Parkinson's disease and Acute Repetitive Seizures ("ARS") in refractory epilepsy patients respectively.

Richard de Souza, CEO of Archimedes, said: "Both these trials have generated exciting results, highlighting the quality of our development capabilities and providing further validation of our business model. We look forward to driving our in-house development projects through to commercialization to provide an ongoing stream of novel products to our rapidly growing pan-European commercial organisation in therapeutic areas in which we already have an established presence. The strength of this strategy is exemplified by our lead development project, NasalFent(R), an intranasal fentanyl spray that has recently shown a best-in class profile for breakthrough cancer pain in our Phase III programme and the regulatory filings for which will begin in the first half of 2009."

Archimedes' IN Apomorphine and IN Diazepam have been developed by applying the world class drug delivery expertise of its subsidiary Archimedes Development lim
'/>"/>

SOURCE Archimedes Pharma Limited
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Adlyfe Strikes Translational Medicine Partnership With Wyeth Pharmaceuticals for Alzheimers Biomarker Assay
2. MAP Pharmaceuticals Announces Phase 3 Study of Unit Dose Budesonide in Children With Asthma Did Not Meet Primary Endpoints
3. AstraZenecas Partner, MAP Pharmaceuticals, Announces Phase 3 Study of Unit Dose Budesonide in Children with Asthma Did Not Meet Primary Endpoints
4. Cordex Pharma Announces Strategic Master Services Equity Agreement With Cato BioVentures
5. Shareholder Class Action Filed Against Rigel Pharmaceuticals, Inc. by the Law Firm of Barroway Topaz Kessler Meltzer & Check, LLP
6. Pharmacyclics, Inc. Announces Closing of a Private Financing With the Principals of Pacific Biopharma Group, Ltd.
7. Access Licenses ProLindac(TM) and MuGard(TM) to JCOM Ltd, an Affiliate of DONG-A Pharmaceuticals in Korea
8. ViroPharma Announces Discontinuation of Maribavir Phase 3 Study in Liver Transplant Patients
9. Inspiration Biopharmaceuticals, Inc. Initiates Phase 1 Clinical Trial of IB1001 for the Treatment of Hemophilia B
10. Endo Pharmaceuticals Announces Research Collaborations to Develop Novel Pain Treatments and Discover Potential Cancer Treatments
11. Sequoia Pharmaceuticals Presents Proof of Clinical Concept of SPI-452, a Novel Pharmacokinetic Enhancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... BURLINGTON, Mass. , Aug. 21, 2014 /PRNewswire/ ... of COPD,  physicians in Brazil ... to follow clinical guidelines and commonly prescribe long-acting ... regimens, although they do so within current severe ... combinations (FDCs) that are expected to launch in ...
(Date:8/21/2014)... , N.Y. and HAMBURG, Germany , Aug. ... it is collaborating with Deutsches Elektronen-Synchrotron ( DESY ), ... , to speed up management and storage of ... Data and Analytics architecture based on IBM software ... second of data at peak performance and help scientists ...
(Date:8/21/2014)... percent of Americans believe the abuse of strong prescription pain ... safety issue in the United States , ... & Partners, a Cincinnati based research ... the prescription medication abuse problem and the need for medical ... facing our country," Rex Repass , CEO of the ...
Breaking Medicine Technology:Novel Fixed-Dose Combinations for COPD in Brazil and Mexico Will Compete With Well-Established Therapies in an Environment Dominated by Aggressive Cost-Control Mechanisms 2Novel Fixed-Dose Combinations for COPD in Brazil and Mexico Will Compete With Well-Established Therapies in an Environment Dominated by Aggressive Cost-Control Mechanisms 3DESY and IBM Develop Big Data Architecture for Science 2DESY and IBM Develop Big Data Architecture for Science 3Consumers Desperate For Measures To Curb Prescription Drug Abuse 2Consumers Desperate For Measures To Curb Prescription Drug Abuse 3
... ASHBURN, Va., Dec. 18 Innocoll, Inc., ... first of three planned,phase 2 clinical trials ... Ltd, to investigate CollaRx(R) GENTAMICIN TOPICAL for ... ulcers, has commenced,dosing., CollaRx GENTAMICIN TOPICAL ...
... RICHMOND, Va., Dec. 18 Insmed Inc. (Nasdaq:,INSM), ... that the Food and Drug Administration (FDA) has ... of Myotonic Muscular,Dystrophy (MMD). Insmed is currently conducting ... MMD, and recently was awarded a grant of,approximately ...
Cached Medicine Technology:Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Mildly Infected Diabetic Foot Ulcers 2Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Mildly Infected Diabetic Foot Ulcers 3Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Mildly Infected Diabetic Foot Ulcers 4Insmed Receives FDA Orphan Drug Designation for IPLEX(TM) in the Treatment of Myotonic Muscular Dystrophy 2Insmed Receives FDA Orphan Drug Designation for IPLEX(TM) in the Treatment of Myotonic Muscular Dystrophy 3
(Date:8/21/2014)... environmental source of fungal infections that have been sickening ... grows on trees. , The discovery is based on ... the summer gathering soil and tree samples from areas ... fungus named Cryptococcus gattii (CRIP-to-cock-us GAT-ee-eye). ... of species including C. gattii , causes life-threatening ...
(Date:8/21/2014)... Black mothers are less likely than white moms to ... Hospitals in neighborhoods with many black residents do less ... white residents, a U.S. government study finds. Key ... medical centers where the black population is higher than ... and Prevention reported Thursday. These practices include efforts ...
(Date:8/21/2014)... Aug. 21, 2014 (HealthDay News) -- Among seniors, dimming ... The study involved more than 2,500 people, aged 65 ... study and again two, six and eight years later. ... the person,s risk of death during the study period, the ... effect, researchers led by Sharon Christ of Purdue University in ...
(Date:8/21/2014)... New York (PRWEB) August 21, 2014 ... against C.R. Bard, Inc. continue to move forward ... District Court, Southern District of West Virginia, Bernstein ... issued on August 14th, the Court has established ... that requires special handling, division, storage and preservation. ...
(Date:8/21/2014)... on her body in terms of how it can ... complete human being with thoughts and feelings. While objectification ... how does it affect individual romantic relationships? New research ... SAGE journal, finds that more objectification of a female ... pressure and coercion., Researchers Laura R. Ramsey and Tiffany ...
Breaking Medicine News(10 mins):Health News:Fungus deadly to AIDS patients found to grow on trees 2Health News:Racial Disparities in Breast-Feeding May Start With Hospitals, Study Suggests 2Health News:Failing Vision Tied to Shorter Lifespans for Seniors 2Health News:Transvaginal Mesh Lawsuits Move Forward in Federal C.R. Bard Litigation with Issuance of New Pretrial Order, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuits Move Forward in Federal C.R. Bard Litigation with Issuance of New Pretrial Order, Bernstein Liebhard LLP Reports 3Health News:Objectification in romantic relationships related to sexual pressure and coercion 2
... analyzing a sample of over 275,000 individuals, has found ... one size does not fit all. , Our study ... and if a person wants to be physically active, ... of Alberta. It is clear that different genders, ethnicities ...
... Day is a,time to celebrate healthy relationships and this ... Give Back A Smile,(GBAS) program celebrates that and so ... time and expertise pro bono to help,restore the smiles ... than 600 GBAS cases have been completed for a ...
... that exercise-trained mice get far fewer gallstones than sedentary ... occurs. , The study, recently published in the ... http://jap.physiology.org/cgi/reprint/01292.2007v1 . , For the first ... gallstone formation, adding to the ever-increasing number of reasons ...
... and Connects Physicians, ... Improves Quality Management, ... leading provider of clinical software, connectivity and,information solutions that ... has selected the Allscripts Electronic Health,Record (EHR) to connect ...
... has been awarded a $1.45 million five-year grant from ... factors that can minimize memory declines in middle-aged and ... behaviors that are tied to better memory and enhanced ... adults believe that memory declines are inevitable and there ...
... tracking the movement of,the prostate during radiation therapy ... Alliance. Featuring tiny GPS-type positioning transponders,implanted inside the ... in real time and alerts technicians if the ... the external beam of,radiation., The advantage of ...
Cached Medicine News:Health News:Study: When it comes to physical activity, one size does not fit all 2Health News:Caring Give Back A Smile Volunteer Dental Professionals Donate Over $5 Million in Services to Survivors of Domestic Violence 2Health News:U of I study: exercise to avoid gallstones! 2Health News:Mankato Clinic Selects Allscripts Electronic Health Record 2Health News:Mankato Clinic Selects Allscripts Electronic Health Record 3Health News:Mankato Clinic Selects Allscripts Electronic Health Record 4Health News:Brandeis researcher awarded grant to investigate memory and aging 2Health News:GPS for the Prostate: System Keeps Radiation Therapy on Target 2
... The Carriazo-Pendular microkeratome is based on ... the cornea during the cut., ,This ... evenly from the beginning of the ... that the intraocular pressure does not ...
... somatomedin-C, is a peptide highly dependent on ... activity. IGF-I is transported in serum by ... growth disorders, measurements of IGF-I are a ... secretion. A normal plasma or serum IGF-I ...
... The IDS OCTEIATM IGF-I kit is a ... Insulin-like Growth Factor-I (IGF-I) in serum or ... polyclonal "capture" antibody in microtiter wells and ... horseradish peroxidase. A simple sample pre-treatment replaces ...
Inquire...
Medicine Products: